CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells.

The histological diagnosis was lymphocytic hypophysitis. Immunostains were positive for CD3 and CD20. Immunostains for acid-fast bacilli, PLAP and OCT3/4 were negative. The patient remains ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx ...

Lunsumio is a CD20/CD3 T cell-engaging bispecific antibody designed to target CD20 on B cells and CD3 on T cells. Lunsumio is expected to activate the immune system through cytotoxic T cells and have ...

If approved, odronextamab would join a few CD20×CD3 bispecific antibodies available in the US. This includes AbbVie and ...

The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies ...

The other study that the company is conducting for Zynlonta is LOTIS-7, a phase 2 trial combining the ADC with the anti-CD20/CD3 bispecific antibody glofitamab. Announced findings from last ...

The deal centres around TNB-486, a bispecific CD19 and CD3 T-cell engager in phase 1 testing ... TNB-486 given alone or in combination with CD20 drugs like rituximab "could potentially deepen ...